NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NRX Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.63+0.03 (+1.15%)
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
NRX Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $113.87M | $197.05M |
| Enterprise Value | $87.18M | $106.56M |
| PS Ratio | 33.55 | 3.93 |
Enterprise value
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 25.69 | 2.69 |
Income (trailing twelve months)
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $3.39M | $57.94M |
| Gross Profit | $1.58M | $90.47M |
| Operating Income | -$19.90M | -$21.44M |
| Net Income | -$23.48M | -$22.46M |
| EBITDA | -$19.70M | -$16.91M |
| EPS (Diluted) | -$0.73 | -$0.83 |
Margins
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 46.6% | 52.3% |
| Operating Margin | -586.2% | -44.5% |
| Profit Margin | -691.8% | -39.2% |
| EBITDA Margin | -580.4% | -31.3% |
Returns
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -120.4% | -41.0% |
| Return on Capital Employed (ROCE) | -6956.3% | -37.8% |
Balance sheet
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $26.69M | $62.42M |
| Net Cash (Debt) | $26.69M | $15.68M |
| Net Cash Per Share | $0.62 | $0.65 |
| Equity (Book Value) | -$170.00K | $48.79M |
| Book Value Per Share | -$0.00 | $1.36 |
| Tangible Book Value | -$2.80M | $23.06M |
| Working Capital | -$4.72M | $75.77M |
Financial position
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.86 | 3.30 |
| Quick Ratio | 0.79 | 2.39 |
| Interest Coverage | -17.39 | -7.12 |
Cash flow (trailing twelve months)
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.77M | -$12.35M |
Efficiency
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.17 | 0.38 |
| Revenue Per Employee | $117.03K | $398.96K |
| Profits Per Employee | -$809.66K | -$732.08K |
| Employee Count | 29 | 73 |
Dividends and yields
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -20.6% | -21.2% |
Shares
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 43,295,800 | 59,128,900 |
| Shares Change (YoY) | 110.5% | 11.1% |
| Shares Change (QoQ) | 28.9% | 0.54% |
| Float | 36,524,700 | 48,744,500 |
| Shares Held by Insiders | 15.6% | 11.8% |
| Shares Held by Institutions | 26.9% | 59.4% |
Taxes
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | NRX Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -13.31 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from NRX Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.